Please assess the completion status of the following clinical trial:

Trial Title: Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem Cells

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • 18 years of age or older;~  * Diagnosis of any phenotypic or genotypic variation of RP, confirmed by clinical history, fundus appearance, visual field (VF), electroretinogram (ERG) and genetic mutation analysis;~ * Having experienced various degrees of VF loss;~ * BCVA from 50 letters to 110 letters in the ETDRS chart testing (Topcon CC-100 XP, Japan);~ * Mean deviation (MD) values ranging between -33.0 and -5.0 dB with Compass visual field analysis (threshold 24-2, Sita Standard, Stimulus 3-white);~ * Intraocular pressure (IOP) of \<22 mmHg.~Exclusion Criteria:~* • The presence of cataracts or other media opacity that might affect the VF, MD, or ERG recordings;~  * The presence of glaucoma, which causes visual field and optic disc changes;~ * The presence of any systemic disorder (e.g.,diabetes, neurological disease, or uncontrolled systemic hypertension) that may affect visual function;~ * The habit of smoking.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Before application (Type: ACTIVE_COMPARATOR): RP patients with progressive visual acuity and visual field loss: before stem cell application.
- After application (Type: ACTIVE_COMPARATOR): RP patients, after stem cell applications.

Based on this trial design, predict the completion outcome and termination type (if applicable).